<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mature B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-NHL) comprises more than 50% of <z:hpo ids='HP_0000001'>all</z:hpo> non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) in children and adolescents </plain></SENT>
<SENT sid="1" pm="."><plain>Many B-NHL subtypes frequently observed in adults are rarely diagnosed in children and adolescents </plain></SENT>
<SENT sid="2" pm="."><plain>In this age group, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), Burkitt <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">FAB L3</z:e> <z:hpo ids='HP_0001909'>leukemia</z:hpo> (B-AL), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), primary mediastinal large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PMLBL), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), and aggressive mature B-NHL not further classifiable (B-NHL nfc) are the most common subtypes </plain></SENT>
<SENT sid="3" pm="."><plain>Diverse clinical trials demonstrated similar results of current combination chemotherapy regimens succeeding in overall survival rates of more than 80% </plain></SENT>
<SENT sid="4" pm="."><plain>However, treatment-related toxicity and the poor prognosis of relapse are serious concerns </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, specific histological B-NHL subtypes are rare in children and optimal treatment is not established </plain></SENT>
<SENT sid="6" pm="."><plain>New treatment modalities are urgently needed for these patient groups </plain></SENT>
<SENT sid="7" pm="."><plain>Rituximab, a monoclonal antibody that is already established in the treatment of adults with mature B-NHL, demonstrated promising results in pediatric patients </plain></SENT>
<SENT sid="8" pm="."><plain>The definitive role of rituximab in the treatment of children and adolescents with B-NHL needs to be evaluated in prospective controlled clinical trials </plain></SENT>
<SENT sid="9" pm="."><plain>This review provides a comprehensive overview of chemotherapy regimens and the perspectives for children and adolescents with mature B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>